Regen BioPharma, Inc. Selects Contract Research Organization to Assist in DuraCAR Experiments

News provided by

Nov 16, 2023, 09:00 ET

SAN DIEGO, Nov. 16, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) The Company has announced that after interviewing several candidates it has selected a Contract Research Organization (CRO) to perform the next set of experiments to elucidate the effectiveness of the Company's DuraCAR cells.

The Company is preparing a series of in vitro studies to test its DuraCAR cells in both immunosuppressive and in tumor-killing experiments. The experiments to explore whether these cells have an immunosuppressive effect include mixing the DuraCAR cells with activated immune cells that are designed to kill target tumor cells and to determine if these cells suppress this killing. In addition, the same experiments will be able to determine if the DuraCAR cells have a direct effect on killing tumors cells.

"We have designed a set of sophisticated experiments that test two hypotheses" says Dr. David Koos, Chairman and CEO of the company. "We have selected a CRO with excellent credentials and we expect the results to lay a clear path forward for this program."

About Regen BioPharma Inc.:

Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

CONTACT INFORMATION:

Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
+1-619-330-2328 Fax
Email: [email protected] or [email protected]
Twitter (now X): https://twitter.com/TheRegenBio

SOURCE Regen BioPharma Inc.